Compare GOSS & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOSS | GAIN |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.7M | 556.7M |
| IPO Year | 2019 | 2005 |
| Metric | GOSS | GAIN |
|---|---|---|
| Price | $2.32 | $13.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $8.83 | ★ $14.75 |
| AVG Volume (30 Days) | ★ 5.5M | 196.5K |
| Earning Date | 03-12-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 10.73% |
| EPS Growth | N/A | ★ 65.30 |
| EPS | N/A | ★ 3.17 |
| Revenue | $44,051,000.00 | ★ $101,433,000.00 |
| Revenue This Year | N/A | $5.70 |
| Revenue Next Year | $6.41 | $6.41 |
| P/E Ratio | ★ N/A | $4.41 |
| Revenue Growth | N/A | ★ 13.00 |
| 52 Week Low | $0.76 | $11.42 |
| 52 Week High | $3.87 | $15.34 |
| Indicator | GOSS | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 52.95 |
| Support Level | $2.24 | $13.80 |
| Resistance Level | $2.41 | $14.10 |
| Average True Range (ATR) | 0.22 | 0.23 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 21.85 | 55.07 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.